LUCID CAPITAL MARKETS Initiates Coverage On Adial Pharmaceuticals with Buy Rating, Announces Price Target of $6
Benzinga Newsdesk 4 months ago
NewsPrice TargetInitiationAnalyst Ratings
LUCID CAPITAL MARKETS analyst Elemer Piros initiates coverage on Adial Pharmaceuticals (NASDAQ:ADIL) with a Buy rating and announces Price Target of $6.
LUCID CAPITAL MARKETS analyst Elemer Piros initiates coverage on Adial Pharmaceuticals (NASDAQ:ADIL) with a Buy rating and announces Price Target of $6.